Fig. 8
miR-10b-5p was an upstream miRNA of TIMM8A in breast cancer. (A) The expression correlation of miR-10b-5p with TIMM8A in breast cancer. (B) Expression of miR-10b-5p in breast cancer and normal tissues based on TCGA database. (C) Kaplan–Meier analysis based on the TCGA database of the effect of miR-10b-5p on progression-free survival in breast cancer. (D) Kaplan–Meier analysis of the 4 patient groups as patients with miR-10b-5p low /TIMM8A high, patients with miR-10b-5p low /TIMM8A low, patients with miR-10b-5p high /TIMM8A low, patients with miR-10b-5p high /TIMM8A high on PFI in breast cancer based on the TCGA database. The median of the ratio was used as the cutoff value. Bonferroni test was used to detect the differences among groups. (E) mRNA expression levels of TIMM8A in MCF7 cells and MDA-MB-231 cells after transfection with miR-10b-5p-mimic analyzed by qRT-PCR. (F–H) Protein expression levels of TIMM8A in MCF7 cells and MDA-MB-231 cells after transfection with miR-10b-5p-mimic analyzed by Western blot. (I) Luciferase reporter plasmids containing the 3’UTR of TIMM8A, with and without mutant miR-10b-5p binding sites. (J) Results of luciferase activity assays. The student’s t-test or one-way ANOVA was used to detect the differences among groups. * P < 0.05, **P < 0.01, ***P < 0.001. Samples were derived from the same experiment and gels/blots were processed in parallel. Original blots/gels are presented in the Supplementary File.
